Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways for treatment of G4-targeted tumors. The investigational compounds within Co.'s RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based to treat a variety of cancer types, including liquid and solid tumors. We show 15 historical shares outstanding datapoints in our QLGN shares outstanding history coverage, used to compute QLGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing QLGN market cap history over the course of time is important for investors
interested in comparing QLGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of QLGN versus a peer is one thing; comparing
QLGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like QLGN can fluctuate over the course of history.
With this page we aim to empower investors researching QLGN by allowing them to research the QLGN market cap history. |
Free QLGN Email Alerts:
Video: The Importance of Market Cap
